HK1246694A1 - α胸腺肽用於脓毒症治疗的用途 - Google Patents

α胸腺肽用於脓毒症治疗的用途 Download PDF

Info

Publication number
HK1246694A1
HK1246694A1 HK18106506.4A HK18106506A HK1246694A1 HK 1246694 A1 HK1246694 A1 HK 1246694A1 HK 18106506 A HK18106506 A HK 18106506A HK 1246694 A1 HK1246694 A1 HK 1246694A1
Authority
HK
Hong Kong
Prior art keywords
sepsis
days
thymosin peptide
alpha
administered
Prior art date
Application number
HK18106506.4A
Other languages
English (en)
Chinese (zh)
Inventor
管向東
管向东
吳健鋒
吴健锋
C．塔特希爾
C.塔特希尔
Original Assignee
Sciclone Pharmaceuticals International (Sg) Pte. Ltd.
中山大学附属第一医院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals International (Sg) Pte. Ltd., 中山大学附属第一医院 filed Critical Sciclone Pharmaceuticals International (Sg) Pte. Ltd.
Publication of HK1246694A1 publication Critical patent/HK1246694A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK18106506.4A 2012-03-30 2018-05-18 α胸腺肽用於脓毒症治疗的用途 HK1246694A1 (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261618563P 2012-03-30 2012-03-30
US61/618,563 2012-03-30
US201261643824P 2012-05-07 2012-05-07
US61/643,824 2012-05-07
US13/835,107 US20130296223A1 (en) 2012-03-30 2013-03-15 Use of thymosin alpha for the treatment of sepsis
US13/835,107 2013-03-15

Publications (1)

Publication Number Publication Date
HK1246694A1 true HK1246694A1 (zh) 2018-09-14

Family

ID=49261395

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18106506.4A HK1246694A1 (zh) 2012-03-30 2018-05-18 α胸腺肽用於脓毒症治疗的用途

Country Status (8)

Country Link
US (5) US20130296223A1 (enExample)
EP (2) EP2841088B1 (enExample)
JP (6) JP2015514093A (enExample)
KR (1) KR20150048663A (enExample)
CN (2) CN107519483A (enExample)
CA (1) CA2866435A1 (enExample)
HK (1) HK1246694A1 (enExample)
WO (1) WO2013149030A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017524943A (ja) * 2014-08-12 2017-08-31 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｓ．アウレウス疾患の予測
WO2019028448A1 (en) * 2017-08-04 2019-02-07 The Johns Hopkins University APPLICATION FOR EARLY PREDICTION OF SEPTIC SHOCK WAITING
US11504071B2 (en) * 2018-04-10 2022-11-22 Hill-Rom Services, Inc. Patient risk assessment based on data from multiple sources in a healthcare facility
SMT202400412T1 (it) * 2018-04-20 2024-11-15 Combioxin Sa Trattamento dell'ipotensione con sepsi o shock settico
WO2023285349A1 (en) 2021-07-12 2023-01-19 2N Pharma Aps Carnitine-palmitoyl-transferase-1 (cpt-1) inhibitors for use in a method of preventing or treating sepsis in a mammalian subject

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079127A (en) 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
WO1995009647A1 (en) * 1993-10-07 1995-04-13 The George Washington University Medical Center METHOD OF TREATING SEPTIC SHOCK USING THYMOSIN-α¿1?
TW252045B (enExample) * 1993-10-07 1995-07-21 Allan L Goldstein
US5972933A (en) * 1998-01-08 1999-10-26 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating microbial infections
UA80957C2 (en) 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
US7897567B2 (en) * 2002-11-25 2011-03-01 Sciclone Pharmaceuticals, Inc. Methods of protecting against radiation damage using alpha thymosin
US9205050B2 (en) * 2005-09-29 2015-12-08 Bayer Intellectual Property Gmbh Antibiotic formulations, unit doses, kits and methods
CN101020048A (zh) * 2007-02-12 2007-08-22 广东天普生化医药股份有限公司 一种用于治疗脓毒症的药物组合物
MX2009009657A (es) * 2007-03-21 2009-09-22 Bausch & Lomb Fluoroquinolonas para el tratamiento, reduccion, mejora, o prevencion de las infecciones provocadas por las bacterias resistentes a los farmacos antibacterianos.
JP2011506436A (ja) * 2007-12-12 2011-03-03 サイクローン・ファーマシューティカルズ・インコーポレイテッド 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
CN101514228A (zh) * 2008-02-21 2009-08-26 张卓兵 N-端修饰的人胸腺肽α1复合物及其制备方法
ES2537785T3 (es) * 2009-05-08 2015-06-12 Sciclone Pharmaceuticals, Inc. Péptidos de alfa timosina como potenciadores de vacunas
EP2416800A1 (en) * 2010-02-25 2012-02-15 Agennix AG Oral lactoferrin in the treatment of severe sepsis
CN103458681A (zh) * 2011-02-09 2013-12-18 赛生制药有限公司 用于预防感染、降低感染的严重性、及治疗感染的胸腺素α肽

Also Published As

Publication number Publication date
CA2866435A1 (en) 2013-10-03
JP2025107346A (ja) 2025-07-17
JP2017214377A (ja) 2017-12-07
JP2019156854A (ja) 2019-09-19
WO2013149030A2 (en) 2013-10-03
KR20150048663A (ko) 2015-05-07
US20240091314A1 (en) 2024-03-21
JP2021100983A (ja) 2021-07-08
JP2015514093A (ja) 2015-05-18
JP2022176345A (ja) 2022-11-25
EP2841088A4 (en) 2015-10-14
CN105338996A (zh) 2016-02-17
CN107519483A (zh) 2017-12-29
US20150024994A1 (en) 2015-01-22
US20180236036A1 (en) 2018-08-23
HK1207314A1 (en) 2016-01-29
EP3741386A1 (en) 2020-11-25
EP2841088B1 (en) 2020-06-17
US20210106656A1 (en) 2021-04-15
EP2841088A2 (en) 2015-03-04
US20130296223A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
US20240091314A1 (en) Use of thymosin alpha for the treatment of sepsis
Egea et al. GM-CSF: a role in immune and inflammatory reactions in the intestine
Alazawi et al. Inflammatory and immune responses to surgery and their clinical impact
Heinen et al. IGF1 treatment improves cardiac remodeling after infarction by targeting myeloid cells
Song et al. Progranulin plays a central role in host defense during sepsis by promoting macrophage recruitment
Blake et al. Role of IL-17 and IL-22 in autoimmunity and cancer
JP2011514881A (ja) 免疫増強剤としてのｔａｍ受容体阻害剤の使用および免疫抑制剤としてのｔａｍ活性化剤の使用
US8212007B2 (en) Expression and purification of HIP/PAP and uses therefor
Baranowsky et al. Procalcitonin exerts a mediator role in septic shock through the calcitonin gene-related peptide receptor
JP5746761B2 (ja) 気道感染症の処置のための方法及び医薬組成物
US20170198011A1 (en) Composition for treating sepsis or septic shock comprising the peptide originated from the smad6
AU2018329850A1 (en) Modified fibroblast growth factor 21 (FGF-21) for use in methods for treating nonalcoholic steatohepatitis (NASH)
EP4084820A1 (en) Fusion proteins and methods of use thereof
EP3586840A1 (en) Novel therapy
US20230416318A1 (en) Osteoanabolism by 14-3-3zeta
US20200121773A1 (en) Compositions and methods for manufacturing bacteriophage cancer vaccines and uses thereof
HK40035899A (en) Use of thymosin alpha for the treatment of sepsis
EP4138881B1 (en) Composition comprising dnase i for use in a method of preventing the activation of the aim2 inflammasome
HK1207314B (en) Use of thymosin alpha for the treatment of sepsis
US20250171546A1 (en) Dupilumab for treatment of covid-19
US20250082734A1 (en) Ptprs in autoimmunity
US20090214469A1 (en) Methods and Compositions for the Treatment of Sepsis
Patel Investigating the Role of Dectin-1 as a Marker of Profibrotic Macrophages in the Progression of Pulmonary Fibrosis
Cavaillon et al. Compartmentalized Activation of Immune Cells During Sepsis and Organ Dysfunction
Javier Munoz et al. Erdheim-Chester Disease: Characteristics and Management